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Abstract: Background: Specific subvariants of uveal melanoma (UM) are associated with increased
rates of metastasis compared to other subvariants. BRCA1 (BReast CAncer gene 1)-associated protein1 (BAP1) is encoded by a gene that has been linked to aggressive behavior in UM. Methods: We
evaluated BAP1 for the presence of intrinsically disordered protein regions (IDPRs) and its protein–
protein interactions (PPI). We evaluated specific sequence-based features of the BAP1 protein using a
set of bioinformatic databases, predictors, and algorithms. Results: We show that BAP1’s structure
contains extensive IDPRs as it is highly enriched in proline residues (the most disordered amino
acid; p-value < 0.05), the average percent of predicted disordered residues (PPDR) was 57.34%, and
contains 9 disorder-based binding sites (ie. molecular recognition features (MoRFs)). BAP1’s intrinsic
disorder allows it to engage in a complex PPI network with at least 49 partners (p-value < 1.0 × 10−16 ).
Conclusion: These findings show that BAP1 contains IDPRs and an intricate PPI network. Mutations
in UM that are associated with the BAP1 gene may alter the function of the IDPRs embedded into its
structure. These findings develop the understanding of UM and may provide a target for potential
novel therapies to treat this aggressive neoplasm.
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1. Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy and has
an age-adjusted incidence of 5.1 per million [1,2]. The neoplasm arises from the melanocytes
in different parts of the uvea, specifically the choroid, ciliary body, or iris. UM comprises
85% of melanomas arising in the eye, with the remainder of eye-related melanomas arising
mostly from the conjunctiva [2]. Most patients present between the ages of 50 years to
70 years and risk factors that have been associated with UM include fair skin, light iris
color, congenital ocular melanocytosis, melanocytoma, and BAP1 cancer predisposition
syndrome [3–6].
UM may present without any symptoms and may be discovered incidentally during a
routine eye examination. However, approximately >70% of patients may have minor visual
disturbances, such as flashes, floaters, or other visual field defects [4]. The diagnosis is
based upon a comprehensive ophthalmic examination, which is followed by further characterization with specialized noninvasive testing methods, such as fundus photography,
ultrasonography, ultrasound biomicroscopy, optical coherence tomography, autofluorescence, and fluorescein angiography [5,7]. Although these non-invasive methods can be
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accurately used in many UM cases, a biopsy of the lesion through fine-needle aspiration
may be necessary to yield a definitive diagnosis [4,8].
When treating UM, the primary goal is complete tumor control for prevention of
metastatic spread and the secondary goal is the preservation of vision if possible. Historically, enucleation was the mainstay of treatment, as this would provide confirmatory
histopathological diagnosis and help guide further decisions. In the 1970s, the treatment
paradigm slowly shifted towards using Iodine-125 (125I) brachytherapy, which is a form
of radiation therapy applied directly over the tumor on the episcleral surface [9,10]. The
Collaborative Ocular Melanoma Study (COMS) showed that there was no significant difference in mortality when comparing 125I brachytherapy to enucleation [11]. This landmark
study now defines how UM is managed.
Today, the American Brachytherapy Society has standardized the use of brachytherapy
to treat UM [12]. Other treatments that are being compared to brachytherapy include
proton beam radiotherapy [13], and smaller tumors may be treated with transpupillary
thermotherapy, photodynamic therapy, photocoagulation, and now investigations into
nanoparticle therapy [14–17]. Although local treatment for primary UM has prevented local
recurrence in over 95% of cases, up to 50% of patients develop hematogenous metastases
that are believed to be micrometastasis even before therapy [5,18,19].
Given the high rates of metastasis following local tumor control, there is a need to
further detail the factors that are driving the aggressive behavior of UM. The rise in precision
and genetic medicine has provided motivation to elucidate the molecular basis of disease,
especially malignancies, including UM. The genomic landscape of UM, characterized by
a small number of highly recurrent mutations, has been studied and profiled via gene
expression profiling (GEP), which has been used as a prognostic tool to predict metastatic
risk [20,21]. GEP can characterize UM tumors in two subgroups: Class 1, which confers a
low metastatic risk, and Class 2, which confers a high metastatic risk [20,21]. Class 2 tumors
contain a cluster of “progression mutations” in SF3B1, EIF1AX, and BAP1 [20,21]. Of
these three genes, BAP1 mutations and loss of function have consistently been linked to
aggressive sub-variants of UM [20,21].
The BRCA1 (BReast CAncer gene 1)-associated protein (BAP1) gene encodes a 729residue-long tumor suppressor protein that functions via multiple incompletely understood
pathways. BAP1 is located on chromosome 3p21.1, which is frequently lost or mutated in
uveal melanoma [21–23]. Mutations in BAP1 consist of missense and nonsense mutations,
frame-shift deletions, non-frame-shift deletion, and four splice site mutations [23]. These
discoveries and associations are key to better understanding UM; however, additional work
is needed to further comprehend how these genetic mutations alter various functions of
this important protein. Specifically, it is unclear how these mutations impact the functional
proteomics of BAP1 and its interaction with other proteins.
Many aspects of UM’s proteome are likely impacted by genetic mutations associated
with the neoplasm. In the interest of our group, we aim to understand UM in the context of the
protein intrinsic disorder phenomenon, focusing on quantifying the intrinsically disordered
protein regions (IDPRs) in BAP1 and characterizing its protein–protein interaction (PPI)
network. IDPRs and intrinsically disordered proteins (IDPs) have been linked to neoplastic
development [24–27]. IDPs and proteins with IDPRs are commonly found in proteomes
of all living organisms and viruses [28–31]. These functional proteins or protein regions
are characterized by the lack of stable 3D structure and possess highly flexible structures
containing multiple functional segments. IDPRs are likely to be involved in an array of diverse
biological functions [32–34]. Our group’s previous studies have demonstrated associations
between IDPRs and the development of ocular surface squamous neoplasia and conjunctival
melanoma [35–37]. Importantly, in a shift from structure-specific drug discovery campaigns,
IDPRs have begun to be targeted to treat various cancers [38–40]. We posit that, like many
other cancer-related proteins, BAP1 has extensive intrinsic structural disorder (i.e., IDPRs). If
BAP1 contains high levels of intrinsic structural disorder, then these molecular features should
be considered as potentially viable targets for future therapies directed at UM.
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2. Materials and Methods
An initial literature search with the key terms “uveal melanoma” and “BAP1” was
done to understand the current treatment landscape of UM and to identify genetic mutations associated with UM. Articles used in the literature search were collected from the
National Library of Medicine MEDLINE databases. All forms of published scientific articles
were considered, including original research, meta-analyses, and systematic reviews. All
articles were limited to publications in the English language. Through our literature search,
we identified 66 unique BAP1 mutations reported by Ewens et al., Decatur et al., and Harbour et al. [21,41,42]. A disorder-based proteomics analysis was also performed to quantify
the levels of intrinsic disorder (i.e., IDPRs) within BAP1 and to assess the complexity of its
PPI network.
2.1. Protein Sequences
The Universal Protein Resource (UniProt; available at: https://uniprot.org; accessed
on 15 June 2022) is a database that houses comprehensive protein information [43]. The
search terms used were “gene: BAP1” and “Homo sapiens (Human)”. The canonical amino
acid sequence in texted-based format (FASTA) was selected from the UniProt entry (UniProt
ID: Q92560).
2.2. Structural Assessment
The UniProt entry used above (UniProt ID: Q92560) also contained structural information. We selected the “AlphaFoldDB” entry as AlphaFold is the most accurate and accepted
computational method to predict structural aspects of proteins [44,45].
2.3. Quantification of Intrinsic Disorder
The BAP1 sequence was subjected to analysis using the Composition Profiler (available
at: http://www.cprofiler.org/; accessed on 15 June 2022) [46]. The profiler allowed for
the analysis of enrichment or depletion of common amino acids in BAP1. The content
of each amino acid in the query protein is compared to background set of proteins that
is comprised of highly structured and ordered proteins, the PDB Select 25 [46]. The
normalized enrichment or depletion is evaluated as (Cx–Corder)/Corder, where Cx is the
content of a given residue in its query protein (i.e., BAP1) and Corder is the content of the
same residue in the PDB Select 25.
The BAP1 sequence was also analyzed using a set of six commonly used per-residue
disorder predictors: PONDR® VLXT [47], PONDR® VL3 [48], PONDR® VLS2 [49,50],
PONDR® FIT [51], and IUPred2 (Short) and IUPred2 (Long) [52,53]. The corresponding
data were assembled using an in-house web crawler that aggregates the outputs of these
six well-known disorder predictors and also provides mean disorder predictions for query
proteins by averaging the outputs of these six predictors. We also used PONDR® VLS2
results to quantify local intrinsic disorder predisposition for each BAP1 mutations that we
identified in the literature.
Potential disorder-related functionality of BAP1 was analyzed using the Database of
Disordered Protein Prediction (D2P2) database (http://d2p2.pro/; accessed on 15 June
2022) [54] that utilizes the outputs of IUPred [52], PONDR® VLXT [47], PrDOS [55],
PONDR® VSL2B [49,50], PV2 [54], and ESpritz [56] to show disorder predispositions of a
query protein and to evaluate agreement between these predictors. The platform also shows
the positions of functional SCOP (Structural Classification of Proteins) domains [57,58]
predicted by the SUPERFAMILY predictor [59]. The D2P2 output also includes information identified by the ANCHOR algorithm, which predicts disorder-based binding sites
that are disordered and expected to fold into ordered structures when they interact with
specific partners (i.e., molecular recognition features (MoRFs)) [60]. The D2P2 platform
also predicts possible posttranslational modifications (PTMs) using the outputs of the
PhosphoSitePlus [61]. Lastly, we analyzed how known UM-related mutations might affect
local disorder propensity of BAP1.
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2.4. Protein–Protein Interaction Network
To assess the potential functional implications of intrinsic disorder in BAP1, we subjected the amino acid sequence to The Search Tool for the Retrieval of Interacting Genes
(STRING) (URL: https://string-db.org/, accessed on 15 June 2022). STRING is a qualitycontrolled database that uses experimentally and computationally derived data to detail
functional interactions between proteins [62]. The STRING search included the canonical
BAP1. The settings for the minimum required interaction score were set to the highest
confidence (0.900), and the maximum number of interactions to show was assigned to the
highest possible value of 500.
3. Results
This section may be divided by subheadings. It should provide a concise and precise
description of the experimental results, their interpretation, as well as the experimental
conclusions that can be drawn.
3.1. Protein Sequence
The canonical amino acid sequence of the BAP1 protein in FASTA format (Figure
S1) was used for our bioinformatics analysis. BAP1 is a deubiquitinating enzyme from
the ubiquitin C-terminal hydrolase (UCH) family that plays a key role in the chromatin
remodeling by mediating deubiquitylation of histone H2A and HCFC1 (Host Cell Factor
C1) [63–66]). The protein sequence consists of 729 amino acids and includes several
functional domains and regions. The domains include (1) a cysteinase domain (or ubiquitin
carboxyl-terminal hydrolase, family 1, residues 1–236), (2) an HBM-like motif (for host cell
factor-1 (HCF-1)-binding motif, NHNY, located within a short sequence (residues 356–385)
that is highly conserved among species [67]), (3) a C-terminal BRCA1 interacting domain
(residues 598–729), which includes a ubiquitin carboxyl-terminal hydrolase UCH37-like
domain (ULD) at residues 675–693 and two nuclear localization sequences (residues 656–661
and 717–722).
3.2. Structural Assessment
The modeled 3D structure of BAP1 modeled by AlphaFold (Figure 1) demonstrates
that the protein has an ordered domain surrounded by long regions of structural disorder.
Within BAP1 structure (see Figure 1), these intrinsically disordered regions appear as stringlike or spaghetti-like segments. Importantly, although these IDPRs do not have definitive
structures, they are likely to be involved in an array of diverse biological functions [32–34].
3.3. Quantification of Intrinsic Disorder
The next phase of our disorder-based computational analysis turned toward quantifying the IDPRs identified in our structural assessment. We first constructed a normalized
composition profile of the amino acids that are part of the BAP1 primary amino acid
sequence (Figure 2). In the corresponding plot, amino acids are arranged from most
order-promoting residues (i.e., cysteine (C), tryptophan (W), isoleucine (I), tyrosine (Y),
phenylalanine (F), leucine (L), histidine (H), valine (V), asparagine (N), and methionine
(M)) to most disorder-promoting residues (i.e., arginine (R), threonine (T), aspartate (D),
glycine (G), alanine (A), lysine (K), glutamine (Q), serine (S), glutamate (E), and proline (P)).
The positive and negative values produced in the composition profile analysis indicated
enrichment or depletion of the indicated residue, respectively. Half (5 of 10) disorderpromoting residues showed enrichment (R, Q, S, E, and P) and only 3 of 10 revealed
enrichment of order-promoting residues (L, H, and V). The most disorder-promoting amino
acid, proline, had the highest relative enrichment of all the amino acids in this protein
(p-value < 0.05). In fact, prolines account for 7.5% of all residues in BAP1, which is significantly higher than the proline content averaged over the entire UniProt database (4.7%). In
addition, BAP1 has a significant proportion of its sequence comprised of other disorder-
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3.3. Quantification of Intrinsic Disorder
The next phase of our disorder-based computational analysis turned toward quantifying the IDPRs identified in our structural assessment. We first constructed a normalized
composition profile of the amino acids that are part of the BAP1 primary amino acid sequence (Figure 2). In the corresponding plot, amino acids are arranged from most orderpromoting residues (i.e., cysteine (C), tryptophan (W), isoleucine (I), tyrosine (Y), phenylalanine (F), leucine (L), histidine (H), valine (V), asparagine (N), and methionine (M)) to
most disorder-promoting residues (i.e., arginine (R), threonine (T), aspartate (D), glycine
(G), alanine (A), lysine (K), glutamine (Q), serine (S), glutamate (E), and proline (P)). The
positive and negative values produced in the composition profile analysis indicated enrichment or depletion of the indicated residue, respectively. Half (5 of 10) disorder-promoting residues showed enrichment (R, Q, S, E, and P) and only 3 of 10 revealed enrichment of order-promoting residues (L, H, and V). The most disorder-promoting amino
acid, proline, had the highest relative enrichment of all the amino acids in this protein (pvalue < 0.05). In fact, prolines account for 7.5% of all residues in BAP1, which is significantly higher than the proline content averaged over the entire UniProt database (4.7%).
In addition, BAP1 has a significant proportion of its sequence comprised of other disorderpromoting residues. These compositional biases indicate that BAP1 has the amino acid
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glycine (G), alanine (A), lysine (K), glutamine (Q), serine (S), glutamate (E), and proline (P)). Positive
values indicate enrichment, and negative values indicate depletion of amino acids. 7 of 10 orderpromoting residues are depleted and 5 of 10 disorder-promoting residues are enriched. Residue
bars marked with * are statistically significant for depletion (i.e., W) or enrichment (i.e., S and P)
(p-value < 0.05)).

After establishing the amino acid composition propensity of BAP1 for the disorder,
we aimed to quantify the intrinsic disorder in this protein. To this end, we utilized six commonly used per-residue predictors of intrinsic disorder to quantify and visualize the IDPRs
in BAP1 (Figure 3A). The tools used in this portion of the study were PONDR® VLXT,
PONDR® VSL2, PONDR® VL3, PONDR® FIT, IUPred short, and IUPred long. These tools
allow for the categorization based on the established criteria for the classification of proteins
based on their PPDR scores, where proteins are considered highly ordered (PPDR < 10%),
moderately disordered (10% ≤ PPDR < 30%), and highly disordered (PPDR ≥ 30%) [68].
These tools indicated that BAP1 is characterized by a high percentage of predicted protein disordered residues (PPDR), which were 53.36% (PONDR® VLXT), 61.04% (PONDR®
VSL2), 57.61% (PONDR® VL3), 50.34% (PONDR® FIT), 43.07% (IUPred short), and 50.21%
(IUPred long). In this analysis, the average PPDR of BAP1 protein is 52.6 ± 4.6%, which
classifies it as highly disordered. These multiparametric disorder evaluation results are in
line with the outputs of the structural analysis of human BAP1 by AlphaFold.
From our literature review, we were able to identify a list of mutations that were
associated with the development of UM. We analyzed the local disorder predispositions of sites affected by these mutations. Results of this analysis are summarized in
Supplementary Table S1, which includes 66 entries. Based on the analysis of 54 UM samples, Ewens et al. reported 52 unique BAP1 mutations that were defined as pathogenic or
likely pathogenic, with 43 tumors carrying somatic mutations, and remaining 11 tumors
carrying germline mutations [42]. Among those mutations, 15 were splice-site mutations
with unknown effects on protein sequence, whereas mutations with known effects on protein sequence include seven missense mutations, three in-frame deletions, and 29 mutations
causing premature truncation [42]. We complemented these data by the results on four
missense, six truncating, and two in-frame deletions reported by Decatur et al. [41], and
also included data on four missense, seven truncating, and four in-frame deletions from
Harbour et al. [21]. Table S1 shows that on average, 66 UM-related mutations in BAP1 are
characterized by the disorder score of 0.48 ± 0.31 PONDR® VSL2 (i.e., high disordered by
PPDR), indicating that many of these mutations affected intrinsically disordered regions.
In fact, 28 mutations happened within highly disordered regions (i.e., regions with the
disorder score exceeding 0.5), 26 mutations were in flexible regions (i.e., regions with the
disorder score ranging from 0.15 to 0.5), and only 12 mutations were in regions predicted
as mostly ordered (i.e., regions with disorder scores below 0.15).
To shed additional light on the potential role of intrinsic disorder in functionality
of BAP1, the D2P2 platform was used (Figure 3B). The D2P2 platform output contains
a corresponding functional disorder profile for BAP1 and shows that in addition to the
presence of high levels of intrinsic disorder, BAP1 is predicted to have 9 MoRFs (residues
258–265, 289–306, 309–326, 330–401, 410–479, 497–508, 526–550, 555–575, and 673–684)
that cover 35.1% of it sequence (or almost 70% of its disordered residues). Furthermore,
BAP1 has multiple phosphorylation sites, two ubiquitination sites and 3 methylation sites,
all located within IDPRs of this protein. BAP1 has a strong tendency for its IDPRs to
be post translationally modified and is in agreement with the well-established fact that
disordered regions of proteins often serve as primary targets for various post-translational
modifications (PTMs) [69–71]. Therefore, BAP1 is highly disordered and can use its intrinsic
disorder for interaction with target proteins, and these interactions are likely to be finetuned via multiple PTMs.
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suppressor gene, which are increasingly targeted for potential therapeutic benefit [73,74].
In light of our findings and in conjunction with recent efforts to target tumor suppressor
genes, future attempts to target molecular features of UM should consider IDPRs in BAP1.
Efforts to target these dynamic, structureless regions of BAP1 may identify solutions not
otherwise considered with traditional structure-focused drug campaigns.
Mutations that impact the intrinsic disorder protein regions (IDPRs) have been implicated in developing other neoplasms, including conjunctival melanoma and ocular surface
squamous neoplasia [35–37]. Dysregulation of disordered regions that leads to dysfunction
of BAP1 may have a role in the development of UM. In line with these considerations, our
analysis of 66 UM-related mutations revealed that they are characterized by the intrinsic
disorder score of 0.48 ± 0.31 as measured by PONDR® VSL2, indicating that many of
these mutations are likely to alter the function of intrinsically disordered regions. We also
show that 28 UM-related mutations happened within highly disordered regions of BAP1,
26 mutations were within moderately disordered regions (i.e., flexible regions), and only
12 mutations (i.e., 18% of all UM-related mutations analyzed in this study) were within the
mostly ordered regions (Table S1).
The mutational landscape of UM is diverse; therefore, there are likely many novel
targets to consider for the management of UM. In the interest of our study, the IDPRs in
BAP1 should be considered. There is evidence that BAP1 mutated UM tumors can be
targeted through poly [ADP-ribose] polymerase (PARP) inhibition, albeit indirectly and in
BAP1 loss tumor cell lines [75]. Other studies have shown that UM contains BAP1 with
missense, nonsense, frame-shift deletions, non-frame-shift deletion, and four splice site
mutations [23]. Another study demonstrated that the ubiquitin carboxyl hydrolase (UCH)
domain in BAP1 is a hotspot region for mutations associated with UM, which lead to the
cytoplasmic sequestration and loss of the protein [76]. Our findings suggest that these
previously characterized mutations may lead to the loss or change of function in BAP1
protein domains and may lead to aberrant regulation of IDPRs. These alterations in IDPRs
of BAP1 may lead to unique DNA methylation profiles as suggested by TCGA [77].
As with all studies, our study has limitations. The databases and tools utilized in this
study do not provide a comprehensive nor exhaustive representation of the UM-related
proteomics. Our work is a bioinformatics-based investigation, and translation to basic
science and clinical outcomes are needed. We did not conduct an in-depth analysis of
where specific mutations are found in BAP1 (i.e., within protein domains or IDPRs). A
future study could provide an additional understanding of the impacts of these mutations
on BAP1 structure, conformational dynamics, and function. Additional bench work will be
needed to determine the role of IDPRs in BAP1. This work may lead to novel targets to
treat specific subtypes of UM. Unfortunately, targeting IDPs and IDPRs by small molecules
remains a challenge and strategies to develop protein disorder-based therapeutics are
limited [36].
In addition to the above limitations, there are other genetic factors that need to be
further studied. We did not include an analysis of other genetic mutations associated with
UM that TCGA has identified, such as GNAQ (Guanine nucleotide-binding protein G(q)
subunit α), GNA11 (Guanine nucleotide-binding protein subunit α-11), EIF1AX (Eukaryotic
translation initiation factor 1A, X-chromosomal), SF3B1 (Splicing factor 3B subunit 1),
CYSLTR2 (Cysteinyl leukotriene receptor 2), SRSF2 (Serine/arginine-rich splicing factor 2),
MAPKAPK5 (MAP kinase-activated protein kinase 5), and PLCB4 (1-phosphatidylinositol
4,5-bisphosphate phosphodiesterase β-4) [77]. There is a strong likelihood that these
proteins also display elements of intrinsic disorder, and additional work will be needed
to confirm this hypothesis and detail the implications. Lastly, while BAP1 mutations are
associated with aggressive subtypes of UM, in some cases, the loss of the entire chromosome
3 were reported (monosomy 3) [78–81]. Therefore, targeting IDPRs in BAP1 may not be a
viable solution in these specific UM subvariants.

Genes 2022, 13, 1703

10 of 13

5. Conclusions
Our study demonstrates that intrinsic disorder in BAP1 may be associated with the development of uveal melanoma. Our group has previously detailed the associations between
intrinsically disordered proteins and the development of ocular surface squamous neoplasia and conjunctival melanoma. Genetic changes associated with BAP1 have been linked to
increased metastatic behavior in uveal melanoma. We found that BAP1 contains intrinsically disorder protein regions (i.e., average percent of predicted disordered residues (PPDR)
was 57.34%) and a complex protein–protein interaction network (p-value < 1.0 × 10−16 ).
Our findings suggest that mutations associated with BAP1 may alter the behavior of intrinsically disordered protein regions, potentially promoting neoplastic development. Better
treatments for UM are needed, and we believe that novel targets should be explored and
include intrinsically disordered protein regions in BAP1.
Supplementary Materials: The following supporting information can be downloaded at: https://www.
mdpi.com/article/10.3390/genes13101703/s1, Figure S1: BAP1’s amino acid sequence; Table S1: UMrelated mutations in human BAP1 gene and local disorder predisposition at sites of mutations in
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